Cytotoxicity and antiestrogenicity of a novel series of basic diphenylethylenes

Journal of Medicinal Chemistry

Volumn 40, Issue 7, 1997, Pages 1104-1111

  Gilbert, Jacques ^a   Fuentes, Maryse ^b   Ojasoo, Tiiu ^b   Doré, Jean Christophe ^b   Pons, Michel ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BIS[4 [2 (DIETHYLAMINO)ETHOXY]PHENYL] 1 HEPTENE; ANTIESTROGEN; CYTOTOXIC AGENT; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; HORMONE INHIBITION; HUMAN; HUMAN CELL; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CRYSTALLOGRAPHY, X-RAY; ESTROGEN ANTAGONISTS; ETHYLENES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0030969731     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950624t     Document Type: Article

References (34)

1. Darbre, P. D.; Daly, R. J. Transition of human breast cancer cells from an oestrogen responsive to unresponsive state. J. Steroid Biochem. Mol. Biol. 1990, 37, 753-763.
2. Murphy, L. C. Estrogen receptor variants in human breast cancer. Mol. Cell. Endocrinol. 1990, 74, C83-C86.
3. Horwitz, K. B. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat. 1993, 26, 119-130.
4. Wolf, D. M.; Jordan, V. C. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res. Treat. 1993, 27, 27-40.
5. Badia, E.; Duchesne, M. J.; Fournier-Bidoz, S.; Simar-Blanchet, A. E.; Terouanne, B.; Nicolas, J. C.; Pons, M. Hydroxytamoxifen induces a rapid and irreversible inactivation of an estrogenic response in an MCF-7-derived cell line. Cancer Res. 1994, 54, 5860-5866.
6. van Agthoven, T.; van Agthoven, T. L. A.; Dekker, A.; Foekens J. A.; Dorssers, L. C. J. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol. Endocrinol. 1994, 8, 1474-1483.
7. Bardon, S.; Vignon, F.; Derocq, D.; Rochefort, H. The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor. Mol. Cell. Endocrinol. 1984, 35, 89-96.
8. Taylor, C. M.; Blanchard, B.; Zava, D. T. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res. 1984, 44, 1409-1414.
9. Sutherland, R. L.; Watts, C. K. W.; Hall, R. E.; Ruenitz, P. C. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J. Steroid Biochem. 1987, 27, 891-897.
10. Clarke, R.; van den Berg, H. W.; Nelson, J.; Murphy R. F. Pharmacological and suprapharmacological concentrations of both 17β-oestradiol and tamoxifen reduce the membrane fluidity of MCF-7 and MDA-MB-436 human breast cancer cells. Biochem. Soc. Trans. 1987, 15, 243-244.
11. van der Koedijk, C. D. M. A.; Vis van Heemst, C.; Elsendoorn, G. M.; Thijssen, J. H. H.; Blankenstein, M. A. Comparative affinity of steroidal and non-steroidal antiestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antiestrogen binding site. Biochem. Pharmacol. 1992, 43, 2511-2518.
12. Rowlands, M. G.; Parr, I. B.; McCague, R.; Jarman, M.; Goddard, P. Variation of the inhibition of calmodulin dependent cAMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem. Pharmacol. 1990, 40, 283-289.
13. O'Brian, C. A.; Liskamp, R. M.; Solomon, D. H.; Weinstein I. B. Triphenyl ethylenes: a new class of protein kinase C inhibitors. J. Natl. Cancer Inst. 1986, 76, 1243-1246.
14. Bignon, E.; Pons, M.; Gilbert, J.; Nishizuka, Y. Multiple mechanisms of protein kinase C inhibition by triphenylacrylonitrile antiestrogens. FEBS Lett. 1990, 271, 54-58.
15. Ojasoo, T.; Bignon, E.; Crastes de Paulet, A.; Doré, J. C.; Gilbert, J.; Miquel, J. F.; Pons, M.; Raynaud, J. P. Relative involvement of the estrogen receptor and protein kinase C in the action of a population of triphenylethylenes on MCF7 cell proliferation as revealed by correspondence factorial analysis (CFA). J. Steroid Biochem. Mol. Biol. 1993, 44, 239-250.
16. Astruc, M. E.; Chabert, C.; Bali, P.; Gagne, D.; Pons, M. Prolonged treatment of breast cancer cells with antiestrogens increases the AP1-mediated response: involvement of the estrogen receptor. Endocrinology 1995, 136, 824-832.
17. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, 1-15, 71-85.
18. Lundgren, S. Prospects in endocrine treatment of breast cancer. Cancer J. 1994, 7, 220-227.
19. 7 cell proliferation. J. Med. Chem. 1992, 35, 573-583.
20. Gilbert, J.; Doré, J. C.; Bignon, E.; Pons, M.; Ojasoo, T. Study of the effects of basic di-and tri-phenyl derivatives on malignant cell proliferation. An example of the application of correspondence factor analysis to structure-activity relationships. Quant. Struct. Act. Rel. 1994, 13, 262-274.
21. Durani, S.; Anand, N. A possible basis for structure-function relationship of estrogens. Int. J. Quant. Chem. 1981, 20, 71-83.
22. Garg, S.; Bindal R. D.; Durani, S.; Kapil, R. S. Structure-activity relationship of estrogens: a study involving cyclofenil as the model compound. J. Steroid Biochem. 1983, 18, 89-95.
23. Bignon, E.; Pons, M.; Crastes de Paulet, A.; Doré, J. C.; Gilbert, J.; Abecassis, J.; Miquel, J. F.; Ojasoo, T.; Raynaud, J. P. Effect of triphenylacrylonitrile derivatives on estradiol receptor binding and on human breast cancer cell growth. J. Med. Chem. 1989, 32, 2092-2103.
24. Doré, J. C.; Gilbert, J.; Ojasoo, T.; Raynaud, J. P. Correspondence analysis applied to steroid receptor binding. J. Med. Chem. 1986, 29, 54-60.
25. Ojasoo, T.; Doré, J. C.; Gilbert, J.; Raynaud, J. P. Binding of steroids to the progestin and glucocorticoid receptors analyzed by correspondence analysis. J. Med. Chem. 1988, 31, 1160-1169.
26. Doré J. C.; Ojasoo, T. Molecular taxonomy by Correspondence Factorial Analysis (CFA) In Advanced Computer-Assisted Techniques in Drug discovery; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1994; pp 190-227.
27. Ojasoo, T.; Raynaud, J. P.; Doré, J. C. Correspondence factor analysis of steroid Libraries. Steroids 1995, 60, 458-469.
28. Pons, M.; Gagne, D.; Nicolas, J. C.; Methali, M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti)estrogen molecules. Biotechniques 1991, 9, 450-459.
29. Demirpence, E.; Balaguer, P.; Trousse, F.; Badia, E.; Gagne, D.; Pons, M. MVLN cells: a bioluminescent MCF-7-derived cell line to study the modulation of estrogenic activity. J. Steroid Biochem. Mol. Biol. 1993, 46, 355-364.
30. Prim, R. C. Shortest connection networks and some generalisations. Bell. Syst. Technol. J. 1957, 36, 1389-1401.
31. Boissier, J. R.; Ratouis, R.; Dumont, C.; Lesbros, J.; Lavaux J. P. New hypercholesterenic tertiary alcohols. Arzeim. Forsch. 1967, 17, 1193-1196.
32. Boissier, J. R.; Ratouis, R. 4-(2-diethylaminoethoxy)phenyl ketones, Pharmaceutical intermediates : French patent no. 1,447,252, July 29, 1966.
33. Brunck, C. F.; Jones, K. C.; James, T. W. Assay for nanogram quantities of DNA in cellular homogenates. Anal. Biochem. 1979, 92, 497-500.
34. Bignon, E.; Pons. M.; Doré, J. C.; Gilbert, J.; Ojasoo, T.; Miquel, J. F.; Raynaud, J. P.; Crastes de Paulet, A. Influence of di-and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem. Pharmacol. 1991, 42, 1373-1383.